Preventing and treating influenza

Stephen G. Baum, Jeanne Carey

Research output: Contribution to journalArticle

Abstract

The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine - inactivated vaccine, which is administered intramuscularly, and attenuated vaccine, which is delivered via nasal spray - have efficacy rates of 70% to 80%. Unfortunately, only about 65% of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70% to 90% effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.

Original languageEnglish (US)
Pages (from-to)477-482
Number of pages6
JournalDrug Benefit Trends
Volume19
Issue number12
StatePublished - Dec 2007

Fingerprint

Zanamivir
Human Influenza
Influenza Vaccines
Rimantadine
Oseltamivir
Nasal Sprays
Amantadine
Attenuated Vaccines
Inactivated Vaccines
Neuraminidase
Inhalation
Antiviral Agents
Vaccination
Therapeutics

Keywords

  • Antiviral therapy
  • Influenza
  • Vaccines

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Baum, S. G., & Carey, J. (2007). Preventing and treating influenza. Drug Benefit Trends, 19(12), 477-482.

Preventing and treating influenza. / Baum, Stephen G.; Carey, Jeanne.

In: Drug Benefit Trends, Vol. 19, No. 12, 12.2007, p. 477-482.

Research output: Contribution to journalArticle

Baum, SG & Carey, J 2007, 'Preventing and treating influenza', Drug Benefit Trends, vol. 19, no. 12, pp. 477-482.
Baum, Stephen G. ; Carey, Jeanne. / Preventing and treating influenza. In: Drug Benefit Trends. 2007 ; Vol. 19, No. 12. pp. 477-482.
@article{00e6208b597a44979fc1c1717505b5de,
title = "Preventing and treating influenza",
abstract = "The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine - inactivated vaccine, which is administered intramuscularly, and attenuated vaccine, which is delivered via nasal spray - have efficacy rates of 70{\%} to 80{\%}. Unfortunately, only about 65{\%} of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70{\%} to 90{\%} effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.",
keywords = "Antiviral therapy, Influenza, Vaccines",
author = "Baum, {Stephen G.} and Jeanne Carey",
year = "2007",
month = "12",
language = "English (US)",
volume = "19",
pages = "477--482",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "12",

}

TY - JOUR

T1 - Preventing and treating influenza

AU - Baum, Stephen G.

AU - Carey, Jeanne

PY - 2007/12

Y1 - 2007/12

N2 - The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine - inactivated vaccine, which is administered intramuscularly, and attenuated vaccine, which is delivered via nasal spray - have efficacy rates of 70% to 80%. Unfortunately, only about 65% of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70% to 90% effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.

AB - The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine - inactivated vaccine, which is administered intramuscularly, and attenuated vaccine, which is delivered via nasal spray - have efficacy rates of 70% to 80%. Unfortunately, only about 65% of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70% to 90% effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.

KW - Antiviral therapy

KW - Influenza

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=38049040809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049040809&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:38049040809

VL - 19

SP - 477

EP - 482

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 12

ER -